← Leaderboards
Till Erdmann
Myelo Therapeutics Gmbh
$6,437,830
Attributed
$6,437,830
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.2M · FY2020–23$2.5M$1.9M$1.3M$625K$0
'20
'21
'22
'23
Funding mix
By agency
NIH$6,437,830 · 1
By mechanism
N01$6,437,830 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Research And Development”
- Leonard Freedman · Leidos Biomedical Research, Inc.$942,960,687
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Lynn Briscoe · Leidos Biomedical Research, Inc.$307,251,504
- Chanza Baytop · Westat, Inc.$271,217,917
Research focus
Research And DevelopmentAnimal SafetyAwardContractsEfficacy StudyHematopoieticHourAnimal EfficacyMedical CountermeasureModel DevelopmentOralPharmaceutical PreparationsPharmacokinetics And PharmacodynamicsPolypharmacyRadiationRadiation ToxicityManufacture
Grant awards (4)
DEVELOPMENT OF MYELO001 AS AN ORALLY APPLIED MEDICAL COUNTERMEASURE FOR THE TREATMENT OF HEMATOPOIETIC ACUTE RADIATION SYNDROME$219,300
N01 · FY2023 · AI · contact PI
DEVELOPMENT OF MYELO001 AS AN ORALLY APPLIED MEDICAL COUNTERMEASURE FOR THE TREATMENT OF HEMATOPOIETIC ACUTE RADIATION SYNDROME$1,996,255
N01 · FY2022 · AI · contact PI
DEVELOPMENT OF MYELO001 AS AN ORALLY APPLIED MEDICAL COUNTERMEASURE FOR THE TREATMENT OF HEMATOPOIETIC ACUTE RADIATION SYNDROME$2,229,043
N01 · FY2021 · AI · contact PI
DEVELOPMENT OF MYELO001 AS AN ORALLY APPLIED MEDICAL COUNTERMEASURE FOR THE TREATMENT OF HEMATOPOIETIC ACUTE RADIATION SYNDROME$1,993,232
N01 · FY2020 · AI · contact PI